Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The cost effectiveness of newer epilepsy treatments: a review of the literature on partial-onset seizures.

Bolin K, Forsgren L.

Pharmacoeconomics. 2012 Oct 1;30(10):903-23. doi: 10.2165/11597110-000000000-00000. Review.

PMID:
22924967
2.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

3.

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.

Health Technol Assess. 2006 Mar;10(7):iii, ix-118. Review.

4.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

5.

Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses.

Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, Saxon D, Kalthenthaler E; group cognitive behavioural therapy for postnatal depression advisory group.

Health Technol Assess. 2010 Sep;14(44):1-107, iii-iv. doi: 10.3310/hta14440. Review.

6.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

7.

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T.

Epilepsia. 2006 Jul;47(7):1094-120. Review.

8.

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.

Craig D, Rice S, Paton F, Fox D, Woolacott N.

Pharmacoeconomics. 2013 Feb;31(2):101-10. doi: 10.1007/s40273-012-0018-1. Review.

PMID:
23341194
9.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

10.

Economic analysis of newer antiepileptic drugs.

Beghi E, Atzeni L, Garattini L.

CNS Drugs. 2008;22(10):861-75. Review.

PMID:
18788837
11.

Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy.

Vera-Llonch M, Brandenburg NA, Oster G.

Epilepsia. 2008 Mar;49(3):431-7. Epub 2007 Sep 5.

12.

Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.

Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, Todd D, Woolacott N.

Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. Review.

13.

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.

14.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

15.

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

D√ľndar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.

Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. Review.

16.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

17.

The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.

Clegg AJ, Loveman E, Gospodarevskaya E, Harris P, Bird A, Bryant J, Scott DA, Davidson P, Little P, Coppin R.

Health Technol Assess. 2010 Jun;14(28):1-192. doi: 10.3310/hta14280. Review.

18.

The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies.

Frew EJ, Sandercock J, Whitehouse WP, Bryan S.

Seizure. 2007 Mar;16(2):99-112. Epub 2006 Dec 11.

19.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

20.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
Items per page

Supplemental Content

Write to the Help Desk